During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...
Researchers review the future of schizophrenia treatment, highlighting TAAR1 agonists, NMDA enhancers, and the gut-brain axis ...
When the researchers administered a long-acting KOR blocking drug to these mice, they found that the agent reduced the expression of the mutant transporter on the cell surface where it normally ...
Morning Overview on MSN
How science and luck sparked a radical new era in schizophrenia treatment
The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a fundamentally new mechanism of action in more than half a century. Built on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results